Navigation Links
Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
Date:8/13/2012

CARLSBAD, Calif., Aug. 13, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has delivered a notice of redemption relating to all of its outstanding 2 ⅝% Convertible Subordinated Notes due 2027 (the "2027 Notes") at a redemption price of 100.75% of the principal amount thereof.  As of August 13, 2012, $162,500,000 aggregate principal amount of the 2027 Notes was outstanding.  The 2027 Notes will be redeemed on September 12, 2012 unless earlier converted.  The CUSIP Numbers of the 2027 Notes are 464337AD6 and 464337AE4.

The 2027 Notes are convertible at any time prior to 5:00 p.m. Eastern Time, September 11, 2012 at a rate of 68.3761 shares of common stock per $1,000 principal amount of the 2027 Notes converted.  If any 2027 Notes are surrendered for conversion, the conversion will be settled in cash.

Wells Fargo Bank, N.A., the trustee for the 2027 Notes, is delivering a Notice of Redemption to all registered holders of the 2027 Notes on August 13, 2012.  Copies of such Notice of Redemption and additional information relating to the procedure for redemption and/or conversion of the 2027 Notes may be obtained from the Wells Fargo Bank, N.A., by calling (800) 344-5128.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis' financial plans, including the planned redemption of the 2027 Notes.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
2. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
3. Intercept Pharmaceuticals Closes $30 Million Series C Financing
4. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
5. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
7. Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency
8. Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
10. Isis Pharmaceuticals Prices Offering of $201.25 Million of 2 3/4% Convertible Senior Notes, Including Exercise in Full of Over-Allotment Option
11. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016   Purdue Pharma ... into an agreement with Egalet Corporation and Acura ... As part of the agreement the companies will ... enable all three companies to develop and sell ... "This agreement reflects the commitment of Purdue ...
(Date:5/20/2016)... 2016 According to the 2016 home ... demand for affordable healthcare solutions as since the early 2000s, ... In countries like the US, the healthcare cost rose faster ... consumer price index inflation rate stood at an average of ... to 3.62% during the same time period. This can be ...
(Date:5/19/2016)... 2016 According to a new market research ... (U.S., Germany , France , ... and Japan )", published by MarketsandMarkets, The market ... CAGR of 13.9% from 2016 to 2021.      (Logo: ... data Tables spread through 26 Pages and in-depth TOC on ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, ... in the development of technological innovations that lead to broad-based healthcare solutions. , ...
(Date:5/24/2016)... ... 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on ... around the world who do not have access to a toilet, even when they’re on ... dread of #perioddrama. The (sometimes hilarious) results help shine a light on the awkwardness that ...
(Date:5/24/2016)... Milwaukee, WI (PRWEB) , ... May 24, 2016 ... ... Facility In Milwaukee , Out patient Services To Begin In June , Aloria ... is pleased to announce the opening of Aloria Milwaukee, its first treatment facility ...
(Date:5/24/2016)... ... 2016 , ... Global Lyme Alliance (GLA), a leading nonprofit ... has named Scott Santarella as its new CEO. , Santarella is former ... San Francisco, where he successfully helped to grow the organization from a regional ...
(Date:5/24/2016)... ... May 24, 2016 , ... Dignity Health has announced ... The new facility is licensed under Dignity Health Arizona General Hospital, which opened ... Dignity Health in Arizona, said that the new facility will complement Dignity Health’s existing ...
Breaking Medicine News(10 mins):